SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

30 May 2023 Evaluate
The topline stands at Rs. 750.20 millions for the March 2023 quarter. The mentioned figure indicates a rise of about 80.77% as against Rs. 415.00 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -196.90 millions as compared to Net Loss of Rs. -253.10 millions of corresponding quarter ended March 2022 Operating profit Margin for the quarter ended March 2023 improved to 137.00% as compared to -168.10% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 750.20 415.00 80.77 2570.70 2355.00 9.16 2570.70 2355.00 9.16
Other Income 102.70 25.70 299.61 344.30 125.70 173.91 344.30 125.70 173.91
PBIDT 137.00 -168.10 -181.50 -281.90 -601.10 -53.10 -281.90 -601.10 -53.10
Interest 27.00 14.40 87.50 100.60 70.40 42.90 100.60 70.40 42.90
PBDT 110.00 -182.50 -160.27 -382.50 -671.50 -43.04 -382.50 -671.50 -43.04
Depreciation 59.00 70.60 -16.43 245.00 264.30 -7.30 245.00 264.30 -7.30
PBT 51.00 -253.10 -120.15 -627.50 -935.80 -32.95 -627.50 -935.80 -32.95
TAX 247.90 0.00 0.00 247.90 0.00 0.00 247.90 0.00 0.00
Deferred Tax 247.90 0.00 0.00 247.90 0.00 0.00 247.90 0.00 0.00
PAT -196.90 -253.10 -22.20 -875.40 -935.80 -6.45 -875.40 -935.80 -6.45
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 18.26 -40.51 -145.08 -10.97 -25.52 -57.04 -10.97 -25.52 -57.04

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×